A Six Week Pharmacokinetic Study of TP-03 in Healthy Subjects

NCT05138861 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: TP-03 (Lotilaner Ophthalmic Solution), 0.25%

Sponsor

Tarsus Pharmaceuticals, Inc.